Kyle Diamantas leads at 35% after stepping into the acting FDA commissioner role following Marty Makary’s May 2026 resignation, while the 33% probability of no announcement by December 31 reflects ongoing White House vetting without a confirmed nominee. Multiple candidates from prior Trump administrations, including Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham, remain under consideration alongside later-reported finalists, creating fragmented support. The closely matched top outcomes stem from procedural uncertainty around Senate confirmation timelines, internal agency transitions, and the absence of a decisive signal from the administration as of mid-August. An official nomination, new public endorsements, or shifts in HHS priorities could quickly consolidate trader views on both timing and the selected individual.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วKyle Diamantas 13%
Brett Giroir 8.6%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 ปริมาณ
$18,953 ปริมาณ
Dec 31, 2026
Kyle Diamantas
35%
Stephen Hahn
6%
Brett Giroir
9%
Grace Graham
4%
Sara Brenner
7%
No announcement by December 31
33%
Kyle Diamantas 13%
Brett Giroir 8.6%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 ปริมาณ
$18,953 ปริมาณ
Dec 31, 2026
Kyle Diamantas
$6,163 ปริมาณ
35%
Stephen Hahn
$1,802 ปริมาณ
6%
Brett Giroir
$3,007 ปริมาณ
9%
Grace Graham
$4,151 ปริมาณ
4%
Sara Brenner
$2,798 ปริมาณ
7%
No announcement by December 31
$1,032 ปริมาณ
33%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads at 35% after stepping into the acting FDA commissioner role following Marty Makary’s May 2026 resignation, while the 33% probability of no announcement by December 31 reflects ongoing White House vetting without a confirmed nominee. Multiple candidates from prior Trump administrations, including Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham, remain under consideration alongside later-reported finalists, creating fragmented support. The closely matched top outcomes stem from procedural uncertainty around Senate confirmation timelines, internal agency transitions, and the absence of a decisive signal from the administration as of mid-August. An official nomination, new public endorsements, or shifts in HHS priorities could quickly consolidate trader views on both timing and the selected individual.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 12, 2026, 7:59 PM ET
ปริมาณการซื้อขาย
$18,953วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads at 35% after stepping into the acting FDA commissioner role following Marty Makary’s May 2026 resignation, while the 33% probability of no announcement by December 31 reflects ongoing White House vetting without a confirmed nominee. Multiple candidates from prior Trump administrations, including Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham, remain under consideration alongside later-reported finalists, creating fragmented support. The closely matched top outcomes stem from procedural uncertainty around Senate confirmation timelines, internal agency transitions, and the absence of a decisive signal from the administration as of mid-August. An official nomination, new public endorsements, or shifts in HHS priorities could quickly consolidate trader views on both timing and the selected individual.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$18,953วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Kyle Diamantas leads at 35% after stepping into the acting FDA commissioner role following Marty Makary’s May 2026 resignation, while the 33% probability of no announcement by December 31 reflects ongoing White House vetting without a confirmed nominee. Multiple candidates from prior Trump administrations, including Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham, remain under consideration alongside later-reported finalists, creating fragmented support. The closely matched top outcomes stem from procedural uncertainty around Senate confirmation timelines, internal agency transitions, and the absence of a decisive signal from the administration as of mid-August. An official nomination, new public endorsements, or shifts in HHS priorities could quickly consolidate trader views on both timing and the selected individual.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย